Success Metrics

Clinical Success Rate
100.0%

Based on 8 completed trials

Completion Rate
100%(8/8)
Active Trials
1(11%)
Results Posted
63%(5 trials)

Phase Distribution

Ph phase_2
5
56%
Ph phase_1
2
22%
Ph phase_3
1
11%
Ph phase_4
1
11%

Phase Distribution

2

Early Stage

5

Mid Stage

2

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
2(22.2%)
Phase 2Efficacy & side effects
5(55.6%)
Phase 3Large-scale testing
1(11.1%)
Phase 4Post-market surveillance
1(11.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

8 of 8 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

9

all time

Status Distribution
Active(1)
Completed(8)

Detailed Status

Completed8
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
1
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (22.2%)
Phase 25 (55.6%)
Phase 31 (11.1%)
Phase 41 (11.1%)

Trials by Status

completed889%
recruiting111%

Recent Activity

1 active trials
Showing 5 of 9
completedphase_2

Study to Expand Safety and Immunogenicity Data With Shigella Bioconjugate Vaccine (Shigella4V2) in 9-month-old Infants.

NCT06523231
completedphase_1

A Study of a Candidate COVID-19 Vaccine (COV001)

NCT04324606
completedphase_2

A Study of 2-dose Vaccination Regimen of Ad26.ZEBOV and MVA-BN-Filo in Infants

NCT03929757
completedphase_1

A Study to Determine If a New Shigella Vaccine is Safe, Induces Immunity and The Best Dose Among Kenyan Infants

NCT04056117
recruitingphase_2

A Study on the Safety, Reactogenicity, and Immune Response to the GVGH iNTS-GMMA Vaccine Against Invasive Nontyphoidal Salmonella in Adults, Children, and Infants

NCT06213506
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT06523231Phase 2

Study to Expand Safety and Immunogenicity Data With Shigella Bioconjugate Vaccine (Shigella4V2) in 9-month-old Infants.

Completed
NCT04324606Phase 1

A Study of a Candidate COVID-19 Vaccine (COV001)

Completed
NCT03929757Phase 2

A Study of 2-dose Vaccination Regimen of Ad26.ZEBOV and MVA-BN-Filo in Infants

Completed
NCT04056117Phase 1

A Study to Determine If a New Shigella Vaccine is Safe, Induces Immunity and The Best Dose Among Kenyan Infants

Completed
NCT06213506Phase 2

A Study on the Safety, Reactogenicity, and Immune Response to the GVGH iNTS-GMMA Vaccine Against Invasive Nontyphoidal Salmonella in Adults, Children, and Infants

Recruiting
NCT02509494Phase 3

Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo

Completed
NCT03433482Phase 2

A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adolescents and Young Adults 10 to 40 Years of Age

Completed
NCT02446691Phase 4

Evaluation of Antibody Persistence Following 4 MenACWY Vaccinations

Completed
NCT02140762Phase 2

Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents

Completed

All 9 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
9